Back To Search Instructions
Protocols
16 protocols meet the specified criteria
Phase: 1
Protocol No.TitleStatus
1603472947Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1612049078A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial TumorsOpen
1701157446METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1702222208A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-FailureOpen
1702242206A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced MalignanciesOpen
1705469245A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic CancersOpen
1706595817A Multicenter, Two Part Open-Label, Phase 1b Clinical Study of CMP-001 Administered Either in Combination with Pembrolizumab or as Monotherapy in Subjects with Advanced MelanomaOpen
1708698450A Phase 1b Study of Intratumoral IMO-2125 in Patients with Refractory Solid Tumors (Illuminate-101)Open
1709868869Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid TumorsOpen
1711993805An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in PatientsOpen
1712087417FIGHT: A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal CancerOpen
1802269227A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid TumorsOpen
1803383790A Phase 1 Study of E6201 for the Treatment of Central Nervous System Metastases (CNS) From BRAF or MEK-Mutated Metastatic MelanomaOpen
1805527255a Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER)Open